Saturday 17 October 2026
Export PEPG’s income statement to Excel — free account
PepGen, Inc.
PEPG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 62.9% and free cash flow grew 33.0%, each against the same quarter a year earlier.
2.60
0.07
+2.77%
Follow PEPG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (75.45%) | (68.40%) | (67.39%) | (62.25%) |
+8 more TTM periods Free account |
|
| (59.06%) | (54.44%) | (55.21%) | (51.93%) | ||
ROIC |
(2,076.25%) | (3,027.47%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(63.85%) | (60.86%) | (63.94%) | (60.06%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.00) | (1.12) | (1.94) | (2.50) | |
Free Cash Flow |
(69.50) | (77.13) | (81.90) | (85.76) | |
Capital Expenditures |
(0.17) | — | (0.26) | (0.49) | |
| Other line items | |||||
Cash ROIC |
(29.36%) | (28.97%) | (27.68%) | (26.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.05 | 0.05 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.96 | 1.00 | 0.91 | 0.91 | |
Depreciation/Fixed assets |
1.65 | 1.75 | 1.54 | 1.23 | |
Capex/Depreciation |
(0.08) | 0.00 | (0.09) | (0.18) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.00) | (1.12) | (1.93) | (2.48) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates